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Abstract
Background: There are limited data regarding the impact of bioresorbable polymer drug eluting stent (BP-DES)
compared to durable polymer drug eluting stent (DP-DES) in patients treated with percutaneous coronary intervention
using ultrathin stents in left main or bifurcations.
Methods: In the RAIN registry (ClinicalTrials NCT03544294, june 2018 retrospectively registered) patients with a ULM or
bifurcation stenosis treated with PCI using ultrathin stents (struts thinner than 81 μm) were enrolled. The primary
endpoint was the rate of target lesion revascularization (TLR); major adverse cardiovascular events (MACE, a composite
of all-cause death, myocardial infarction, TLR and stent thrombosis) and its components, along with target vessel
revascularization (TVR) were the secondary ones. A propensity score with matching analysis to compare patients
treated with BP-DES versus DP-DES was also assessed.
Results: From 3001 enrolled patients, after propensity score analysis 1400 patients (700 for each group) were selected.
Among them, 352 had ULM disease and 1048 had non-LM bifurcations. At 16months (12–22), rates of TLR (3.7% vs
2.9%, p = 0.22) and MACE were similar (12.3% vs. 11.6%, p = 0.74) as well as for the other endpoints. Sensitivity analysis
of outcomes after a two-stents strategy, showed better outcome in term of MACE (20.4% vs 10%, p = 0.03) and TVR
(12% vs 4.6%, p = 0.05) and a trend towards lower TLR in patients treated with BP-DES.
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Conclusion: In patients with bifurcations or ULM treated with ultrathin stents BP-DES seems to perform similarly to DP-
DES: the trends toward improved clinical outcomes in patients treated with the BP-DES might potentially be of value
for speculating the stent choice in selected high-risk subgroups of patients at increased risk of ischemic events.
Trial registration: ClinicalTrials.gov Identifier: NCT03544294. Retrospectively registered June 1, 2018.
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Background
The treatment of unprotected left main and of coronary
bifurcation still represents a challenge for interventional
cardiologists due to both procedural complications and
higher restenosis rates compared with non-bifurcation
lesions [1–4].
The complexity of the bifurcation milieu is rooted into
the unique flow patterns that characterized them, with local
low and oscillatory endothelial shear stress along the lateral
walls of the main vessel and of the side branch, whereas
high endothelial shear stress develops at the carina. This
ultimatey leads to a prothrombotic and atherogenic flow-
pattern, and even after treatment with percutaneous coron-
ary intervention (PCI), it may increase the failure rate wit
need for subsequent revascularization on the target lesion
(TLR) and an increased risk of stent thrombosis (ST) [4–6].
In the last years, BP-DES (Bioresorbable polymer drug
eluting stents) have been introduced with the rationale to
potentially decrease ST. Differently from durable polymer
stents (DP), after the elution of the antiproliferative drug
the bioreabsorbable polymer is going to dissolve leaving
behind a bare metal stent, thus reducing the local inflam-
matory reactions and therefore the risk of thrombosis re-
lated to a permanent polymer. Clinically, this translated
into lower rates of TLR for BP-DESs implanted in coron-
ary bifurcations in the LEADER-FREE [7], although this
RCT was weakened by the comparison with a first gener-
ation stent. Regarding currently implanted second gener-
ation DES, both in the EVOLVE II trial and in a recent
paper of Mennuni et al. [8, 9], BP-DESs were shown to be
safe and effective as compared to durable polymer, al-
though coronary bifurcations and LM were underrepre-
sented (respectively about 4 and 15%) [10].
In light of the intrinsic limitations of the above studies,
the RAIN study (very thin stents for patients with MAIN
or bifurcation in real life: the RAIN, a multicenter study)
was designed to evaluate the clinical performance of ultra-
thin stents in everyday clinical practice. We here present
an analysis of the RAIN study aimed to evaluate the safety
and efficacy of BP-DES in the bifurcation setting.
Methods
The RAIN is a large multicenter retrospective observa-
tional registry (ClinicalTrials NCT03544294, retrospect-
ively registered; see Additional file 1 for enrolling sites).
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and are con-
sistent with ICH Good Clinical Practice as well as regu-
latory requirements. It was approved by an institutional
review committee, and all patients provided informed
consent.
Inclusion criteria
The RAIN registry included all consecutive patients from
June 2015 to January 2017 undergoing complex PCI involv-
ing LM and/or bifurcation with ultrathin stents (Promus
Element, Xience Alpine, Ultimaster, Synergy, and Resolute
Onyx; see Additional file 1 for more details on the stents
involved in this study).
Baseline and procedural data
Cardiovascular risk factors, clinical presentation, angio-
graphic features, use of IntraVascular UltraSound
(IVUS), Optical Coherence Tomography (OCT) and
Fractional Flow Reserve (FFR) were recorded, along with
the characteristics of the implanted stents. IVUS or
OCT was used prior to stent implantation to assess the
severity of the stenosis and side branch involvement,
and post stent implantation to evaluate dissection and
the requirement for stent optimisation. The decision
to post-dilate, to perform final kissing balloon (FKB),
to assess intracoronary imaging and the choice of the
stenting technique (provisional versus 2-stent), was at
the discretion of the treating physician.
The above data were derived from electronic patient re-
cords at each center, while follow-up data were obtained
from clinical assessment, telephonic consultations or via
primary care physicians and then recorded online (http://
www.cardiogroup.org/RAIN/index.php?cat=home).
Endpoints
The rate of TLR was the primary endpoint, while MACE (a
composite endpoint of all-cause death, myocardial infarc-
tion, TLR and stent thrombosis) and its components, along
with TVR were the secondary endpoints. The analyses were
performed according to PCI strategy (provisional vs two-
stent).
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Statistical analysis
Categorical variables are reported as count and percent-
ages, whereas continuous variables as mean and standard
deviations or interquartile range (IQR). Gaussian or not
Gaussian distribution was evaluated by Kolmogorov-
Smirnoff test. The t-test has been used to assess differences
between parametric continuous variables, Mann-Whitney
U test for non parametric variables, the chi-square test for
categorical variables and Fisher’s exact test for 2 × 2 tables.
The a priori statistical significance level was set at α = 0.05.
To account for clustered data among centres we used a
normal regression (ANOVA) approach with a fixed effect
for cluster and an effect for group when data were nor-
mally distributed. For non-normal data, we used the Wil-
coxon rank sum test modified to account for clustering.
For propensity score, first logistic regression analysis was
done for all baseline features that differed between BP-DES
and DP-DES, matching was computed after division into
quintiles and methods of the 1:1 nearest neighbor on the
estimated propensity score [11]. Calibration was tested
with Hosmer-Lermeshow, and accuracy was assessed with
Area Under the Curve. Standardized differences were eval-
uated before and after matching to evaluate the perform-
ance of the model. All statistical analyses were performed
with SPSS 21 and differences were considered significant at
α = 0.05.
Results
Before propensity score with matching
At the end of the enrolling period 3001 patients had
been recorded: 2120 were treated with DP-DES ad 881
with BP-DES (see Fig. 1).
At baseline patients in the BP-DES were more hyperten-
sive (28.8% vs 23.2% in the DP group, p < 0.01), with a
higher rate of previous MI (35.3% vs 26.6% in the DP group,
p < 0.01) and they were more often admitted due to STEMI
(19.1% vs 16%, p < 0.01). On the other side, patients with
DP-DES were more often hyperlipidemic (58.1% vs. 54.6%
in the BP group, p < 0.01; see Additional file 1: Table A).
Patients with BP-DES more frequently presented diffuse
coronary disease (55.1% vs 29.9%% in the DP group, p <
0.01), and with true bifurcation involvement (i.e. Medina
1,1,1 or 0,1,1; 28.1% in the BP group vs 17.5% in the DP
group, p < 0.001). They were less frequently treated with
two-stent technique (76.9% vs 82.4% in the DP group, p <
0.01). Finally, there was a similar rate of total ULM disease
(30% vs 26.9%, p = 0.45) (see Additional file 1: Table B).
After propensity score with matching
After multivariate adjustment, 700 patients for each
group were selected. Baseline clinical features were com-
parable, with similar rates of presentation for STEMI
(19% in the DP group vs. 18.1% in the BP group, p = 0.1,
see Table 1 and Fig. 1).
At angiography, similar percentages of patients had a
LM disease (23.1% in the DP group vs 27.1% in the BP
group, p = 0.87) and true bifurcation involvement (19.7%
in the DP group vs 21.9% in the BP group, p = 0.5).
Provisional strategy was successfully performed in both
groups in the majority of patients (82.1% in the DP
group vs. 82.2% in the BP group, p = 0.68, see Table 2).
At a median follow up of 16 (12–22) months, rates of
TLR (3.7% vs 2.9%, p = 0.22) and MACE were similar
Fig. 1 design of the study
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(12.3% vs. 11.6%, p = 0.74), without significant differences
among all the secondary endpoint (see Fig. 2).
At sensitivity analysis for patients treated with two
stents strategy, patients treated with BP-DES showed a
better outcome in term of MACE (20.4% vs 10% in the
DP group, p = 0.03) and TVR (12% vs 4.6% in the DP
group, p = 0.05, see Fig. 3) and a trend towards TLR
(3.7% vs 2.9%, p = 0.22).
Discussion
Our main findings may be summarised as follows:
 Among patients treated for Left Main disease, the
risk of MACE was similar for BP-DES and DP-DES.
 Among patients treated with two stents strategy in
both LM and non-LM bifurcation involvement,
patients treated with BP-DES showed a better
outcome in term of MACE and TVR.
 No differences in ST are evident in BP-DES com-
pared to DP-DES group.
To the best of our knowledge, this is the first real-world,
observational registry evaluating the safety and efficacy
profile of different ultrathin stents (struts thinner than
81 μm) in patients with a ULM stenosis treated with PCI
using newer-generation abluminal BP- DES as compared
to the DP-DES.
BP-DES have been developed to combine the best of
both family of metallic stents, i.e. the efficacy of DES and
the late safety associated with BMS. However, the available
evidences on cardiac death, MI, or stent thrombosis are still
scarce [12–17]: network meta-analyses have indicated an
excess risk of BP-DES with regard to MI or stent throm-
bosis when compared with DP-EES (i.e. Xience, Abbott
Vascular, Santa Clara, California), though their results were
restricted due to heterogeneity of devices in the BP-DES
group and to limited follow-up duration [12–14]. Of note,
the meta-analyses by Kang et al. [12] and by Navarese et al.
[14] included BP-BES trials using the Biosensors BioMatrix
device (Biosensors International, Singapore), the meta-
analysis of Bangalore et al. [13] included also trials using an
other sirolimus-eluting stent (SES) with biodegradable
polymer (Yukon Choice PC, Translumina, Hechingen,
Germany) while the one by Cassese et al. [15] included






Age (mean ± SD) 70.7 ± 9 70.7 ± 10 0.97
Female (%) 20.5 23.1 0.24
Hypertension (%) 77.1 73.8 0.17
Hyperlipidemia (%) 62 63.8 0.5
Diabete mellitus non ID (%) 26.2 27.8 0.5
Diabete mellitus ID (%) 6.4 9.5 0.09
Previous smoker (%) 31.8 30.3 0.5
Renal Disease (gfr < 60 ml/min/m2) (%) 19.7 19.9 0.71
Previous PCI (%) 32 33.6 0.57
Previous CABG (%) 4.9 4.4 0.7
Previous MI (%) 31.8 36 0.1
ASA + Clopidogrel (%) 64.3 66.4 0.25
ASA + Ticagrelor (%) 24.2 23.8 0.22
ASA + Prasugrel (%) 7.6 8.0 0.11
Length of DAPT (months) 11.3 11.7 0.34
Indication for PCI: (%) 0.1
- STEMI 19 18.1
- NSTEMI 25.4 27.8
- UA 18.2 14.7
- Stable angina 14.9 21.6
- Planned angiographic follow up 7.1 4.9






Radial access (%) 69.7 68.9 0.77
Overall LM (%) 23.1 27.1 0.87
Site of lesion: 0.11
- Ostial LM 23.9 25.5
- Mid LM 46.8 49.3
- Distal LM 19.9 16.3
Type C lesion (%) 44.3 41.9 0.37
Severe calcification (%) 13.2 14 0.68
Diffuse disease (%) 52.5 55.9 0.23
Bifurcation site (%) 0.13
- Distal LM 27.4 30.7
- LAD/Dg 45.9 48.4
- LCx/Om 19.1 15.4
- RCA/Pl 7.5 5.6
True bifurcation (medina 1,1,1 or 0,1,1) 19.7 21.9 0.5
Provisional strategy (%) 82.1 82.2 0.9
2 stents technique strategy (%) 0.1
- Culotte 1.7 1.6
- Mini crush 4.1 5
- Crush 0.5 0.8
- DK-crush 0.3 0.6
- T stent 4.4 2.8
- TAP stent 3.9 3.7
Use of imaging: 0.09
- IVUS 29.9 34.2
- OCT 0.9 1.6
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trials on the ultrathin sirolimus-eluting Orsiro device (Bio-
tronik, Bülach, Switzerland).
The principal finding of our current analysis is that
BP-DES actually showed a similar safety and efficacy
profile at 5 years compared with the DP-DES. Notably -
apart from ST - event rates in our study were low keep-
ing into account the clinical and anatomical complexity
of the enrolled patients, and similar to previous studies
on new-generation DES [16, 17]. These data reflect the
global improvement in quality and safety outcomes of
these devices mainly due to either the effect of anti-
proliferative drug on restenosis and either to the thin
struts technology that facilitate the endothelial coverage.
However in our study the whole population analysis did
Fig. 2 outcomes at follow-up. Blue columns represent the percentage of events among patients receiving a DP-DES, red columns represent the
percentage of events among patients receiving a BP-DES
Fig. 3 outcomes at follow-up in the subgroup of patients in whom a coronary bifurcation was treated with a 2-stent technique. Blue columns
represent the percentage of events among patients receiving a DP-DES, red columns represent the percentage of events among patients
receiving a BP-DES
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not show differences between patients who received BP-
DES compared to DP-DES: this might be due to the
overwhelming benefit of the thin strut design over the
polymer material: the difference in adverse events is in
fact observed during period of time that is shorter than
the complete polymers dissolution time. These findings
highlight the importance of the overall DES design and
biocompatibility on the clinical performance of contem-
porary DES [3]. The effect of stent’s struts thickness has
been well established already, with thinner struts show-
ing to produce less inflammation, vessel injury, neointi-
mal proliferation, as well as thrombus formation when
compared with thicker ones [18, 19]. Furthermore, the
5-year analysis of the COMPARE II trial also confirmed
the early- and mid-term similar safety and efficacy of the
BP-BES and the DP-EES, thus challenging the concept
itself of the biodegradable polymer coating [20, 21]. On
the other hand, Bayesian analysis in the BIOFLOW-V
trial, despite limited by the analysis itself and by the par-
ticular thickness of the stent used, is encouraging for an
actual role of bioresorbable polymers [22, 23]. Therefore,
whether BP-DES are as safe and effective as DP-DES
should be proven for each specific stent by an appropri-
ately designed clinical trial.
The second interesting result is the trend towards bet-
ter outcome in term of MACE and TVR in patients
treated with BP-DES and a two stents strategy. The
higher risk of subsequent events in this challenging ana-
tomical subset is well known, and it is related either to
patient either to technique drawbacks [23, 24]. Despite
the low percentage of patients included in this analysis
(about 20% of the patients selected by propensity score),
we can speculate that in an high risk setting like a
double stent bifurcation treatment in left main disease,
the added value of a bioresorbable polymer in terms of
vessel recovery as above explained might really make the
difference in terms of outcomes. Of course, this thesis
should come on top of more strong assumption about the
outcomes related to the use of two stents in bifurcation,
most important the technique used [2, 23].
As regard the percentage of stent thrombosis we found,
we should not forget that such high numbers are actually
in line with other real life reports with comparable follow-
up [24]. Furthermore, our study enrolled consecutive all-
comers patients, reflecting real practice outcomes that are
obviously different from the safer environment of ran-
domized trial. The percentages in the whole population
analysed are actually similar to what reported in the
COMPARE I trial (A Trial of Everolimus-Eluting Stents
and Paclitaxel Stents for Coronary Revascularization in
Daily Practice) of 1.8% [25] and of the LEADERS trial
(Limus Eluted From a Durable Versus Erodable Stent
Coating) of 2.6% [8]. These findings stress the importance
of correct identification of critical bifurcation disease by
means of fraction flow reserve or intravascular imaging [26,
27] and the value of longer double anti-platelet therapy in
patients with higher thrombotic risk [28], especially when
this anatomical feature comes together with higher clinical
risk situation like ACS [29–31].
Limitations
There are several limitations to this study. First, this was
not a randomized controlled study: with the use of pro-
pensity score we could not adjust for variables which
were not possible to collect (e.g. the experience of the
physicians performing PCI) or others among multiple
factors that might be implicated in DES acute thrombo-
genicity and long-term vascular healing (e.g. the the
polymer biocompatibility, its composition and distribu-
tion, and -in case of bioresorbable polymers- the dur-
ation of bioresorption [3, 17, 21]). It is difficult to assess
the different contribution of all these confounding fac-
tors in a single study. Furthermore, the amount of pa-
tients who received a two-stent treatment for bifurcation
disease is small compared to the one who received the
provisional approach. Finally, although designed as an all
comers study, only 23% of patients undergoing percutan-
eous interventions were actually enrolled in the study, so
selection bias cannot be entirely ruled out.
Conclusion
The main message is that BP-DES look as safe as DP-DES
even in high anatomical risk setting like LM disease. Fur-
thermore, the provisional approach confirms itself as the
safer on the long term. Finally, when a two-stent strategy
is absolutely needed, the trends toward improved clinical
outcomes with respect to MACE and TVR we found with
BP-DES might potentially be of value to speculate about
the stent choice in selected high-risk subgroups of patients
at increased risk of ischemic events.
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